Revelation Biosciences
REVB
2 hedge funds and large institutions have $427K invested in Revelation Biosciences in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
27% less capital invested
Capital invested by funds: $589K → $427K (-$162K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6K |
| 3 |
Two Sigma Investments
New York
|
-$5K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3K |
| 5 |
Renaissance Technologies
New York
|
-$3K |
REVB Hedge Fund Activity: Q4 2022 in Review
2 of the 6,232 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q4 2022, worth a combined $427K — down 27% from $589K a quarter earlier.
Fund positioning in REVB was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Millennium Management, cutting an estimated $13K.
- 2 institutional investors held Revelation Biosciences (REVB) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $427K of Revelation Biosciences stock for Q4 2022, down 27% quarter-over-quarter.
- 0 funds opened new Revelation Biosciences positions in Q4 2022 and 0 closed out.
- The largest Revelation Biosciences seller in Q4 2022 was Millennium Management, an estimated $13K sold.
Based on aggregated 13F filings for Q4 2022.